

Paolo Prandoni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3010456/paolo-prandoni-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

7,021
citations

32
h-index

83
g-index

96
ext. papers

8,166
ext. citations

8.6
avg, IF

5.39
L-index

#	Paper	IF	Citations
94	No difference in outcome between therapeutic and preventive anticoagulation in patients with superficial vein thrombosis involving the saphenous-femoral junction.. <i>Vascular Medicine</i> , 2022 , 1358863	3.2	211066962
93	New perspectives for prevention of the post-thrombotic syndrome 2022 , 1, 24-28		
92	Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021 , 61, 9-82	2.3	69
91	Edoxaban for the Long-Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?. <i>Clinical and Translational Science</i> , 2021 , 14, 335-342	4.9	
90	The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study. <i>Internal and Emergency Medicine</i> , 2021 , 16, 997-1003	3.7	2
89	Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux. <i>Haematologica</i> , 2021 ,	6.6	1
88	Post-thrombotic syndrome. <i>Vasa - European Journal of Vascular Medicine</i> , 2021 , 50, 331-340	1.9	1
87	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , 2020 , 4, e446-e456	2.7	1
86	The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. <i>Internal and Emergency Medicine</i> , 2020 , 15, 447-452	3.7	13
85	On the questionable ethics of randomizing patients with acute DVT to receive rivaroxaban or warfarin. <i>Surgery</i> , 2020 , 167, 515	3.6	
84	Is there a link between venous and arterial thrombosis? A reappraisal. <i>Internal and Emergency Medicine</i> , 2020 , 15, 33-36	3.7	6
83	Low reproducibility of the diagnosis of subsegmental pulmonary embolism in symptomatic patients. <i>Thrombosis Research</i> , 2019 , 175, 6-7	8.2	0
82	Determinants of severe post-thrombotic syndrome: The role of thrombus location. <i>Thrombosis Research</i> , 2019 , 178, 171-172	8.2	1
81	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , 2019 , 104, e474-e477	6.6	0
80	Usefulness of CHADS-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019 , 124, 1059-1063	3	5
79	A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism. <i>Thrombosis Research</i> , 2018 , 165, 107-111	8.2	18
78	Predictors of Post-Thrombotic Ulcer after Acute DVT: The RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 320-328	7	18

77	Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. <i>Lancet Haematology, the</i> , 2018 , 5, e25-e33	14.6	50
76	Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). <i>Thrombosis and Haemostasis</i> , 2018 , 118, 214-224	7	101
75	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018 , 39, 4208-4218	9.5	156
74	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018 , 168, 121-129	8.2	10
73	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , 2018 , 170, 75-83	8.2	4
72	Risk and prognosis of cancer after upper-extremity deep venous thrombosis: A population-based cohort study. <i>Thrombosis Research</i> , 2018 , 161, 106-110	8.2	9
71	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018 , 2, 788-796	7.8	46
70	Trans-popliteal reflux in limbs with and without deep-vein thrombosis of the same subject: Cross-sectional study. <i>Thrombosis Research</i> , 2017 , 154, 53-54	8.2	1
69	Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. <i>Cancer Medicine</i> , 2017 , 6, 1165-1172	4.8	46
68	Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. <i>Thrombosis Research</i> , 2017 , 153, 97-100	8.2	24
67	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017 , 376, 1211-1222	59.2	397
66	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017 , 7, 16950	3	5
65	The impact of deep vein thrombosis on the risk of subsequent cardiovascular events: a 14-year follow-up study. <i>International Angiology</i> , 2017 , 36, 156-159	2.2	4
64	The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 906, 89-100	3.6	
63	The Treatment of Venous Thromboembolism in Patients with Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 906, 123-135	3.6	5
62	Does the presence of clinical symptoms of pulmonary embolism affect the outcome of patients with deep vein thrombosis?. <i>Thrombosis Research</i> , 2017 , 157, 134-135	8.2	
61	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017 , 12, 1291-1305	3.7	14
60	An association between residual vein thrombosis and subclinical atherosclerosis: Cross-sectional study. <i>Thrombosis Research</i> , 2017 , 157, 16-19	8.2	6

59	Controversies in the management of cancer-associated thrombosis. <i>Expert Review of Hematology</i> , 2017 , 10, 15-22	2.8	15
58	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017 , 149, 29-37	8.2	10
57	Pregnancy-related venous thromboembolism and risk of occult cancer. <i>Blood Advances</i> , 2017 , 1, 2059-2068	0.8	1
56	Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants. <i>International Angiology</i> , 2017 , 36, 395-401	2.2	3
55	Inter-observer variability of compression ultrasound for the assessment of residual vein thrombosis. <i>Thrombosis Research</i> , 2016 , 145, 1-2	8.2	5
54	Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. <i>New England Journal of Medicine</i> , 2016 , 375, 1524-1531	59.2	135
53	Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 733-8	7	42
52	An unusual finding of massive pulmonary embolism in a patient during treatment with high-dose ibuprofen. <i>Aging Clinical and Experimental Research</i> , 2016 , 28, 167-8	4.8	0
51	Post-thrombotic syndrome and the risk of subsequent recurrent thromboembolism. <i>Thrombosis Research</i> , 2016 , 141, 91-2	8.2	14
50	High rate of inter-observer agreement between professional-rated scores of the Villalta scale for the assessment of the post-thrombotic syndrome. <i>Thrombosis Research</i> , 2016 , 144, 182-3	8.2	2
49	The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 133-40	5.3	58
48	Residual vein thrombosis and the risk of subsequent serious complications. <i>Thrombosis Research</i> , 2015 , 136, 178-9	8.2	7
47	Incidence of arterial embolism in patients on treatment with old and new anticoagulants for venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 154-9	5.3	2
46	Duration of anticoagulation after venous thromboembolism in real world clinical practice. <i>Thrombosis Research</i> , 2015 , 135, 666-72	8.2	42
45	Pulmonary embolism: Epidemiology and registries. <i>Presse Medicale</i> , 2015 , 44, e377-83	2.2	14
44	Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 1210-5	7	15
43	Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. <i>Thrombosis Research</i> , 2015 , 136, 917-23	8.2	15
42	Fondaparinux in the initial and long-term treatment of venous thromboembolism. <i>Thrombosis Research</i> , 2015 , 135, 311-7	8.2	13

41	Venous thromboembolism in 2013: the advent of the novel oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2014 , 11, 70-2	14.8	6
40	Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. <i>Circulation</i> , 2014 , 130, 1062-71	16.7	190
39	Thromboprophylaxis in medical inpatients with cancer. <i>American Journal of Medicine</i> , 2014 , 127, e11	2.4	3
38	What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 799-807	4	1
37	The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. <i>Circulation</i> , 2014 , 130, 1636-61	16.7	331
36	The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. <i>European Journal of Internal Medicine</i> , 2014 , 25, 25-30	3.9	15
35	Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 172-9	7	70
34	Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. <i>Thrombosis Journal</i> , 2014 , 12, 25	5.6	41
33	Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. <i>Thrombosis Research</i> , 2014 , 134, 227-33	8.2	15
32	Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials. <i>Seminars in Hematology</i> , 2014 , 51, 121-30	4	7
31	Residual vein thrombosis and trans-popliteal reflux in patients with and without the post-thrombotic syndrome. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 854-5	7	34
30	Venous thromboembolism and arterial complications. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012 , 33, 205-10	3.9	12
29	Fondaparinux for the treatment of superficial-vein thrombosis in the legs. <i>New England Journal of Medicine</i> , 2010 , 363, 1222-32	59.2	227
28	Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. <i>British Journal of Haematology</i> , 2008 , 141, 587-97	4.5	32
27	Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 773-7	5.9	20
26	Should cancer patients receive thromboprophylaxis to prevent catheter-related upper limb deep vein thrombosis?. <i>Internal and Emergency Medicine</i> , 2008 , 3, 85-6	3.7	3
25	The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. <i>Haematologica</i> , 2007 , 92, 199-205	6.6	573
24	Endothelial dysfunction in patients with spontaneous venous thromboembolism. <i>Haematologica</i> , 2007 , 92, 812-8	6.6	80

23	Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. <i>Lancet, The</i> , 2007 , 370, 1773-9	40	302
22	Cancer, thrombosis and heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2007 , 120 Suppl 2, S137-40	8.2	44
21	New strategies for the treatment of acute venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 787-92	5.3	5
20	Thrombosis as a harbinger of cancer. <i>Current Opinion in Hematology</i> , 2006 , 13, 362-5	3.3	7
19	Low-molecular-weight heparins for the long-term treatment of cancer patients with venous thromboembolism. <i>The Journal of Supportive Oncology</i> , 2006 , 4, 127-8		1
18	Acquired risk factors for venous thromboembolism in medical patients. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 2005, 458-61	3.1	23
17	Cancer and venous thromboembolism. <i>Lancet Oncology, The</i> , 2005 , 6, 401-10	21.7	454
16	How I treat venous thromboembolism in patients with cancer. <i>Blood</i> , 2005 , 106, 4027-33	2.2	41
15	Emerging strategies for treatment of venous thromboembolism. <i>Expert Opinion on Emerging Drugs</i> , 2005 , 10, 87-94	3.7	1
14	Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. <i>Archives of Internal Medicine</i> , 2004 , 164, 1077-83		85
13	Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. <i>Annals of Internal Medicine</i> , 2004 , 141, 249-56	8	481
12	The optimal long-term treatment of venous thromboembolism. <i>Clinical Advances in Hematology and Oncology</i> , 2004 , 2, 729-32	0.6	2
11	An association between atherosclerosis and venous thrombosis. <i>New England Journal of Medicine</i> , 2003 , 348, 1435-41	59.2	470
10	Recurrent thromboembolism in cancer patients: incidence and risk factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2003 , 29 Suppl 1, 3-8	5.3	11
9	Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. <i>Annals of Internal Medicine</i> , 2002 , 137, 955-60	8	355
8	Antithrombotic Strategies in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 141-144	7	42
7	The long-term clinical course of acute deep venous thrombosis. <i>Annals of Internal Medicine</i> , 1996 , 125, 1-7	8	1485
6	Antiphospholipid Antibodies, Recurrent Thromboembolism, and Intensity of Warfarin Anticoagulation. <i>Thrombosis and Haemostasis</i> , 1996 , 75, 859-859	7	24

5	Comparison of Real-Time B-Mode Ultrasonography and Doppler Ultrasound with Contrast Venography in the Diagnosis of Venous Thrombosis in Symptomatic Outpatients. <i>Thrombosis and Haemostasis</i> , 1993 , 70, 404-407	7	32
4	Contrast Venography, the Gold Standard for the Diagnosis of Deep-Vein Thrombosis: Improvement in Observer Agreement. <i>Thrombosis and Haemostasis</i> , 1992 , 67, 08-12	7	71
3	Deep Vein Thrombosis and Fibrinolysis. <i>Thrombosis and Haemostasis</i> , 1991 , 66, 426-429	7	16
2	Confirmation of the Failure of Computerized Impedance Plethysmography in the Diagnostic Management of Patients with Clinically Suspected Deep-Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1991 , 66, 744-744	7	
1	The Natural History of Venous Thromboembolism27-52		